DURECT Corp. (DRRX) is a leading biotherapeutics company transforming acute organ injury and chronic liver diseases treatment by using its epigenetic regulator program. The company’s lead pipeline candidate Larsucosterol or DUR-928 treats hypermethylation in alcohol-associated hepatitis patients. Additionally, POSIMIR is a non-opioid analgesic that uses SABER platform technology.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of DRRX stock during the regular trading on February 11, 2022, was $0.70 with a 3.71% decline. At last check in the aftermarket, the stock surged by 6.97%.
DRRX: Events and Happenings
On February 11, 2022, DRRX updated about a recent filing with SEC (Form 8-K) regarding unscheduled material events or corporate events. On January 6, 2022, DRRX reported about the presence of its Executive management at the H.C. Wainwright Bioconnect Conference on January 10, 2022.
On December 22, 2021, DRRX updated about its licensing agreement grant to Innocoll Biotherapeutics, proprietary development, and commercialization rights to POSIMIR. On November 29, 2021, DRRX informed about its management’s participation at the 5th Annual Virtual NASH Summit on December 2, 2021.
On November 12, 2021, DRRX updated about the presentation of its data regarding an increase of hospitalizations for AH at the American Association for the Study of Liver Diseases Liver Meeting. On November 10, 2021, DRRX announced the dosage of the initial patient as part of its AHFIRM Phase 2 trials to assess the efficacy and safety of larsucosterol.
DRRX: Key Financials
On November 2, 2021, DRRX released its financial results for the three months ended September 30, 2021. Some of the key aspects are mentioned below.
Revenue
Total revenue in Q3 2021 was $2.2 million compared to $1.8 million in the same quarter in 2020. The company beat the analysts’ estimates by $215 thousand.
EPS
Basic and diluted net loss per share in Q3 2021 was $10 million or $0.04 against $9.3 million or $0.05 in the same quarter in 2020. The company beat the analysts’ estimates of EPS by $0.01 per share.
Conclusion
DRRX stock is 45% down the past six months as the economy slows down in the pandemic. The current premarket stock rebound can likely be associated with the recent Form 8-K filing with SEC. The analysts estimated revenue of approximately $2.10 million and EPS in the range of -$0.05 per share.
